



**AI-Enabled Respiratory  
Remote Patient Monitoring Device**

# Current Respiratory Monitoring Devices


## Capnography ETCO<sub>2</sub>



Capnography is the **GOLD STANDARD** for respiratory monitoring and detecting respiratory-related complications.



## Pulse Oximetry SpO<sub>2</sub>



Measures the oxygen level (saturation) in red blood cells.

# Current Respiratory Monitoring Devices

- **Tethered**
- **Cumbersome**
- **Limits Mobility**
- **Prohibitive (\$10-15k)**




# Capnesity: Transformational Respiratory Monitoring



 **Capnesity**<sup>TM</sup>



# Capnesity Remote Monitoring Cloud Platform



**Continuous Patient Respiratory Condition Data Collection**

# Business Model – Hospital Pain Points

- Respiratory related hospital admissions is a **top source** of **financial loss** for U.S. Hospitals
  - ↑ High cost of care
  - ↓ Low Reimbursement
  - + Frequent Readmissions

# Business Model – Remote Home Monitoring



## Device

**Estimated MSRP: \$900**

**Unit Cost: \$300**

**Profit Margin: 67%**

---

**Refurbished:  
Reclamation Unit Cost: \$150**

**Profit Margin: 83%**

## Hospital Profit Margin \$8.1M Improvement\*

**Bed Days Gained: 3,400**

**Telemonitoring Revenue: \$900\*\***

**Added Bed Revenue: \$1,930\*\***

**Hospital Margin Including a 10%  
estimated reduction in  
readmissions:  
\$2,400\*\***

\* Modeled annual savings for a 450 Bed Hospital in the Mid South using publicly available data. Estimated one month of monitoring for CPT Codes: 99453, 99454, 99091 and 99457/8).

\*\* Per bed day gained with timely discharges.

# Capnesity Team

## Health and Science Team



Jeff Gibson  
Inventor & Founder

[LinkedIn](#)



Dr. Joshua Spicer  
Chief Executive Officer

[LinkedIn](#)



Dr. Greg Auner  
Chief Science Officer

[LinkedIn](#)



Dr. Ryan Sexton  
Chief Medical Officer

[LinkedIn](#)

## Business and Technology Team



Robert Panah  
Finance

[LinkedIn](#)



Runako Godfrey  
Technology

[LinkedIn](#)



William Parks, Esq  
Legal


[LinkedIn](#)



Mike Thomas  
Commercialization

[LinkedIn](#)

# Traction & Timeline






**Capnesity™**

**AI-Enabled Respiratory  
Remote Patient Monitoring Device  
For Optimizing Hospital Profits**

**THANK YOU**

Contact: Dr. Joshua Spicer | [jspicer@capnesity.com](mailto:jspicer@capnesity.com)

# Market Opportunity



## Target U.S. Market-2023 Data:

- Treatment Cost for Respiratory Diseases: **\$171 B**
- Hospital Readmission Costs: **\$43 B**
- Telehealth Market: **\$50 B, CAGR 24%**
- Respiratory Device Market: **\$24 B, CAGR 6%**
- Hospital Systems: **417 systems with 800K beds**
- Hospital Systems: **HCA 37K beds-VA 25K beds-Top Ten 185K beds**
- Respiratory/Cardiac Related Admissions: **19% - 34%**
- Average Hospital Stay / New Capnesity Device: **Every 4.7 Days**

## Commercialization Strategy:

- ✓ **Beachhead Market:** Remote Monitoring (after 1<sup>st</sup> 510k approval) for State of Vermont Critical Access Hospitals; remote monitoring study at Regional One Health with parallel commercial focus on early adopter hospital systems.
- ✓ **Home Monitoring Market:** Remote home monitoring (after 2<sup>nd</sup> home use 510k approval) for hospital systems on a non-exclusive basis.
- ✓ **Drug Delivery System Market:** Capnesity holds the only patent that allows wireless notification of capnography data to drug delivery systems (estimated at 300,000-450,000 units deployed in the U.S). We estimate annually, 14 new Capnesity devices would connect to each pump.
- ✓ **Big Data Market:** Targeting data aggregators or Federal or State users benefiting from disease specific and population insights.